{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:29:17Z","timestamp":1792290557308,"version":"4.4.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s11883-019-0787-5","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T22:03:11Z","timestamp":1556661791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Current Role of Lipoprotein Apheresis"],"prefix":"10.1007","volume":"21","author":[{"given":"Gilbert","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus G.","family":"Parhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"key":"787_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11883-014-0465-6","volume":"17","author":"C Stefanutti","year":"2015","unstructured":"Stefanutti C, Thompson GR. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr Atheroscler Rep. 2015;17:465.","journal-title":"Curr Atheroscler Rep"},{"key":"787_CR2","volume-title":"Wellcome witnesses to twentieth century medicine","author":"NB Myant","year":"2006","unstructured":"Myant NB. Plasma cholesterol as a cause of coronary heart disease (CHD); the cholesterol - CHD hypothesis. In: Reynolds LM, editor. Wellcome witnesses to twentieth century medicine, vol. 27. London: The Wellcome Trust; 2006."},{"key":"787_CR3","first-page":"1377","volume":"118","author":"JL de Gennes","year":"1967","unstructured":"de Gennes JL, Touraine R, Maunand B, Truffert J, Laudat P. [Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis an heroic treatment]. Bull Mem Soc Med Hop Paris. 1967;118:1377\u2013402.","journal-title":"Bull Mem Soc Med Hop Paris"},{"key":"787_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(75)92193-5","volume":"1","author":"GR Thompson","year":"1975","unstructured":"\u2022\u2022 Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1975;1:1208\u201311 First report demonstrating that cholesterol can be lowered by extracorporeal treatment modality. The study also included 14 C- cholesterol turnover experiments, elucidating the pathway of cholesterol removal.","journal-title":"Lancet"},{"key":"787_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0140-6736(81)91213-7","volume":"2","author":"W Stoffel","year":"1981","unstructured":"\u2022\u2022 Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet. 1981;2:1005\u20137 First selective apheresis device to decrease LDL-cholesterol. The method is based on binding apoB containing lipoproteins to a column and thus eliminating LDL particles from plasma.","journal-title":"Lancet"},{"key":"787_CR6","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/0026-0495(93)90065-V","volume":"42","author":"WO Richter","year":"1993","unstructured":"Richter WO, Jacob BG, Ritter MM, Suhler K, Vierneisel K, Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism. 1993;42:888\u201394.","journal-title":"Metabolism"},{"key":"787_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/jca.20135","volume":"22","author":"U Julius","year":"2007","unstructured":"Julius U, Parhofer KG, Heibges A, Kurz S, Klingel R, Geiss HC. Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis--comparison of performance characteristics with DALI and lipid filtration. J Clin Apher. 2007;22:215\u201323.","journal-title":"J Clin Apher"},{"key":"787_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0021-9150(87)90089-X","volume":"68","author":"H Mabuchi","year":"1987","unstructured":"Mabuchi H, Michishita I, Takeda M, Fujita H, Koizumi J, Takeda R, et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis. 1987;68:19\u201325.","journal-title":"Atherosclerosis"},{"key":"787_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1161\/01.ATV.5.6.613","volume":"5","author":"S Yokoyama","year":"1985","unstructured":"Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis. 1985;5:613\u201322.","journal-title":"Arteriosclerosis"},{"key":"787_CR10","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1525-1594.1993.tb00609.x","volume":"17","author":"T Bosch","year":"1993","unstructured":"Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs. 1993;17:640\u201352.","journal-title":"Artif Organs"},{"key":"787_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF01728226","volume":"65","author":"T Eisenhauer","year":"1987","unstructured":"Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr. 1987;65:161\u20138.","journal-title":"Klin Wochenschr"},{"key":"787_CR12","first-page":"406","volume":"26","author":"T Agishi","year":"1980","unstructured":"Agishi T, Kaneko I, Hasuo Y, Hayasaka Y, Sanaka T, Ota K, et al. Double filtration plasmapheresis. Trans Am Soc Artif Intern Organs. 1980;26:406\u201311.","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"787_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.transci.2004.01.008","volume":"30","author":"R Klingel","year":"2004","unstructured":"Klingel R, Mausfeld P, Fassbender C, Goehlen B. Lipidfiltration--safe and effective methodology to perform lipid-apheresis. Transfus Apher Sci. 2004;30:245\u201354.","journal-title":"Transfus Apher Sci"},{"key":"787_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0002-9149(97)00947-8","volume":"81","author":"BR Gordon","year":"1998","unstructured":"Gordon BR, Kelsey SF, Dau PC, Gotto AM Jr, Graham K, Illingworth DR, et al. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. Am J Cardiol. 1998;81:407\u201311.","journal-title":"Am J Cardiol"},{"key":"787_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/jca.21406","volume":"31","author":"JP Drouin-Chartier","year":"2016","unstructured":"Drouin-Chartier JP, Tremblay AJ, Bergeron J, Pelletier M, Laflamme N, Lamarche B, et al. Comparison of two low-density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia. J Clin Apher. 2016;31:359\u201367.","journal-title":"J Clin Apher"},{"key":"787_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2018.08.051","volume":"277","author":"Collaboration EASFHS, Investigators EASFHSC","year":"2018","unstructured":"Collaboration EASFHS, Investigators EASFHSC. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018;277:234\u201355.","journal-title":"Atherosclerosis"},{"issue":"Suppl 1","key":"787_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11789-017-0089-9","volume":"12","author":"VJ Schettler","year":"2017","unstructured":"Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, et al. The German lipoprotein apheresis registry (GLAR) - almost 5 years on. Clin Res Cardiol Suppl. 2017;12(Suppl 1):44\u20139.","journal-title":"Clin Res Cardiol Suppl"},{"key":"787_CR18","doi-asserted-by":"publisher","first-page":"e003294","DOI":"10.1161\/JAHA.116.003294","volume":"5","author":"A Wang","year":"2016","unstructured":"Wang A, Richhariya A, Gandra SR, Calimlim B, Kim L, Quek RG, et al. Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. J Am Heart Assoc. 2016;5:e003294. https:\/\/doi.org\/10.1161\/JAHA.116.003294 .","journal-title":"J Am Heart Assoc"},{"key":"787_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","volume":"173","author":"F Civeira","year":"2004","unstructured":"Civeira F, International Panel on Management of Familial H. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173:55\u201368.","journal-title":"Atherosclerosis"},{"key":"787_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","volume":"5","author":"AC Goldberg","year":"2011","unstructured":"Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:133\u201340.","journal-title":"J Clin Lipidol"},{"key":"787_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.5551\/jat.14621","volume":"19","author":"M Harada-Shiba","year":"2012","unstructured":"Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb. 2012;19:1043\u201360.","journal-title":"J Atheroscler Thromb"},{"key":"787_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11789-012-0046-6","volume":"7","author":"V Schettler","year":"2012","unstructured":"Schettler V, Neumann CL, Hulpke-Wette M, Hagenah GC, Schulz EG, Wieland E, et al. Current view: indications for extracorporeal lipid apheresis treatment. Clin Res Cardiol Suppl. 2012;7:15\u20139.","journal-title":"Clin Res Cardiol Suppl"},{"key":"787_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/jca.20240","volume":"25","author":"ZM Szczepiorkowski","year":"2010","unstructured":"Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for apheresis. J Clin Apher. 2010;25:83\u2013177.","journal-title":"J Clin Apher"},{"key":"787_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","volume":"198","author":"GR Thompson","year":"2008","unstructured":"Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198:247\u201355.","journal-title":"Atherosclerosis"},{"key":"787_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ijcard.2013.11.025","volume":"171","author":"GF Watts","year":"2014","unstructured":"Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol. 2014;171:309\u201325.","journal-title":"Int J Cardiol"},{"key":"787_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0021-9150(78)90157-0","volume":"31","author":"CS Apstein","year":"1978","unstructured":"Apstein CS, Zilversmit DB, Lees RS, George PK. Effect of intessive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia. Atherosclerosis. 1978;31:105\u201315.","journal-title":"Atherosclerosis"},{"key":"787_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2016.10.017","volume":"255","author":"M France","year":"2016","unstructured":"France M, Rees A, Datta D, Thompson G, Capps N, Ferns G, et al. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis. 2016;255:128\u201339.","journal-title":"Atherosclerosis"},{"key":"787_CR28","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0140-6736(95)92961-4","volume":"345","author":"GR Thompson","year":"1995","unstructured":"Thompson GR, Maher VM, Matthews S, Kitano Y, Neuwirth C, Shortt MB, et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 1995;345:811\u20136.","journal-title":"Lancet"},{"key":"787_CR29","doi-asserted-by":"crossref","first-page":"e13053","DOI":"10.1111\/eci.13053","volume":"49","author":"L Ma","year":"2019","unstructured":"Ma L, Waldmann E, Ooi EMM, Chan DC, Barrett HPR, Watts GF, et al. Lipoprotein (a) and low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease. Eur J Clin Investig. 2019;49:e13053.","journal-title":"Eur J Clin Investig"},{"key":"787_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","volume":"152","author":"AA Kroon","year":"2000","unstructured":"Kroon AA, van't Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis. 2000;152:519\u201326.","journal-title":"Atherosclerosis"},{"key":"787_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","volume":"208","author":"GR Thompson","year":"2010","unstructured":"Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis. 2010;208:317\u201321.","journal-title":"Atherosclerosis"},{"key":"787_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2018.08.007","volume":"277","author":"S Beliard","year":"2018","unstructured":"Beliard S, Gallo A, Duchene E, Carrie A, Bittar R, Chapman MJ, et al. Lipoprotein-apheresis in familial hypercholesterolemia: long-term patient compliance in a French cohort. Atherosclerosis. 2018;277:66\u201371.","journal-title":"Atherosclerosis"},{"key":"787_CR33","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","volume":"37","author":"PM Moriarty","year":"2016","unstructured":"\u2022\u2022 Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016;37:3588\u201395 In this study it was shown that the PCSK9-inhibitor alirocumab can enable many patients with heterozygous FH to avoid apheresis.","journal-title":"Eur Heart J"},{"key":"787_CR34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","volume":"5","author":"FJ Raal","year":"2017","unstructured":"\u2022 Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017;5:280\u201390 This study shows that the PCSK9-inhibor evolocumab can decrease the frequency of apheresis in some patients with homozygous FH.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"787_CR35","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331\u201340.","journal-title":"Lancet"},{"key":"787_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40\u20136.","journal-title":"Lancet"},{"key":"787_CR37","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.atherosclerosis.2015.03.014","volume":"240","author":"C Stefanutti","year":"2015","unstructured":"Stefanutti C, Blom DJ, Averna MR, Meagher EA, Theron H, Marais AD, et al. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a phase 3, single-arm, open-label trial. Atherosclerosis. 2015;240:408\u201314.","journal-title":"Atherosclerosis"},{"key":"787_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2017.02.019","volume":"259","author":"E Waldmann","year":"2017","unstructured":"Waldmann E, Vogt A, Crispin A, Altenhofer J, Riks I, Parhofer KG. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (the MICA-study). Atherosclerosis. 2017;259:20\u20135.","journal-title":"Atherosclerosis"},{"key":"787_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.atherosclerosis.2018.07.032","volume":"276","author":"GR Thompson","year":"2018","unstructured":"Thompson GR. Atherosclerosis in cholesterol-fed rabbits and in homozygous and heterozygous LDL receptor-deficient humans. Atherosclerosis. 2018;276:148\u201354.","journal-title":"Atherosclerosis"},{"key":"787_CR40","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.atherosclerosis.2015.09.029","volume":"243","author":"GR Thompson","year":"2015","unstructured":"Thompson GR, Seed M, Naoumova RP, Neuwirth C, Walji S, Aitman TJ, et al. Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes. Atherosclerosis. 2015;243:328\u201333.","journal-title":"Atherosclerosis"},{"key":"787_CR41","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2015.01.007","volume":"239","author":"B Lefort","year":"2015","unstructured":"Lefort B, Saheb S, Bruckert E, Giraud C, Hequet O, Hankard R. Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia. Atherosclerosis. 2015;239:158\u201362.","journal-title":"Atherosclerosis"},{"key":"787_CR42","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","volume":"39","author":"GR Thompson","year":"2018","unstructured":"\u2022 Thompson GR, Blom DJ, Marais AD, Seed M, Pilcher GJ, Raal FJ. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. 2018;39:1162\u20138 Unequivocal demonstration that longevity in homozygous FH is determined by the extent of reduction in serum cholesterol achieved by the combination of apheresis and lipid-lowering drug therapy.","journal-title":"Eur Heart J"},{"key":"787_CR43","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/eurheartj\/ehx438","volume":"39","author":"RM Stoekenbroek","year":"2018","unstructured":"Stoekenbroek RM, Kees Hovingh G, Kastelein JJP. Homozygous familial hypercholesterolaemia: light at the end of the tunnel. Eur Heart J. 2018;39:1169\u201371.","journal-title":"Eur Heart J"},{"key":"787_CR44","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844\u201353.","journal-title":"Eur Heart J"},{"key":"787_CR45","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","volume":"3","author":"S Burgess","year":"2018","unstructured":"Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018;3:619\u201327.","journal-title":"JAMA Cardiol"},{"key":"787_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"MJ Landray","year":"2014","unstructured":"Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203\u201312.","journal-title":"N Engl J Med"},{"key":"787_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.atherosclerosissup.2012.10.015","volume":"14","author":"MS Safarova","year":"2013","unstructured":"Safarova MS, Ezhov MV, Afanasieva OI, Matchin YG, Atanesyan RV, Adamova IY, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl. 2013;14:93\u20139.","journal-title":"Atheroscler Suppl"},{"key":"787_CR48","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.atherosclerosissup.2017.05.007","volume":"30","author":"WC Poller","year":"2017","unstructured":"Poller WC, Berger A, Dreger H, Morgera S, Enke-Melzer K. Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study. Atheroscler Suppl. 2017;30:174\u20139.","journal-title":"Atheroscler Suppl"},{"key":"787_CR49","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.transci.2018.07.015","volume":"57","author":"F Bigazzi","year":"2018","unstructured":"Bigazzi F, Sbrana F, Berretti D, Maria Grazia Z, Zambon S, Fabris A, et al. Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. Transfus Apher Sci. 2018;57:661\u20134.","journal-title":"Transfus Apher Sci"},{"key":"787_CR50","first-page":"229","volume":"6","author":"BR Jaeger","year":"2009","unstructured":"\u2022 Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6:229\u201339 The first study that showed that the cardiovascular event rate decreases dramatically after initiation of regular apheresis of patients with raised Lp(a); although the reduction is impressive, the data must be interpreted with caution as the study lacks a control group .","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"787_CR51","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","volume":"128","author":"J Leebmann","year":"2013","unstructured":"Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013;128:2567\u201376.","journal-title":"Circulation"},{"key":"787_CR52","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/aor.12135","volume":"38","author":"A Rosada","year":"2014","unstructured":"Rosada A, Kassner U, Vogt A, Willhauck M, Parhofer K, Steinhagen-Thiessen E. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? Artif Organs. 2014;38:135\u201341.","journal-title":"Artif Organs"},{"key":"787_CR53","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1194\/jlr.R056549","volume":"57","author":"E Waldmann","year":"2016","unstructured":"Waldmann E, Parhofer KG. Lipoprotein apheresis to treat elevated lipoprotein (a). J Lipid Res. 2016;57:1751\u20137.","journal-title":"J Lipid Res"},{"key":"787_CR54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.pathol.2018.10.016","volume":"51","author":"E Waldmann","year":"2019","unstructured":"Waldmann E, Parhofer KG. Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). Pathology. 2019;51:227\u201332.","journal-title":"Pathology"},{"issue":"4","key":"787_CR55","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000095425","volume":"73","author":"AV Kyriakidis","year":"2006","unstructured":"Kyriakidis AV, Raitsiou B, Sakagianni A, Harisopoulou V, Pyrgioti M, Panagopoulou A, et al. Management of acute severe hyperlipidemic pancreatitis. Digestion. 2006;73(4):259\u201364.","journal-title":"Digestion"},{"key":"787_CR56","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.3748\/wjg.v10.i15.2272","volume":"10","author":"JH Chen","year":"2004","unstructured":"Chen JH, Yeh JH, Lai HW, Liao CS. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. World J Gastroenterol. 2004;10:2272\u20134.","journal-title":"World J Gastroenterol"},{"key":"787_CR57","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/MPA.0000000000000507","volume":"45","author":"CT Chang","year":"2016","unstructured":"Chang CT, Tsai TY, Liao HY, Chang CM, Jheng JS, Huang WH, et al. Double filtration plasma apheresis shortens hospital admission duration of patients with severe hypertriglyceridemia-associated acute pancreatitis. Pancreas. 2016;45:606\u201312.","journal-title":"Pancreas"},{"key":"787_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.transci.2016.10.005","volume":"56","author":"S Nakhoda","year":"2017","unstructured":"Nakhoda S, Zimrin AB, Baer MR, Law JY. Use of the APACHE II score to assess impact of therapeutic plasma exchange for critically ill patients with hypertriglyceride-induced pancreatitis. Transfus Apher Sci. 2017;56:123\u20136.","journal-title":"Transfus Apher Sci"},{"key":"787_CR59","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0026-0495(98)90063-4","volume":"47","author":"PH Barrett","year":"1998","unstructured":"Barrett PH, Parhofer KG. Low-density lipoprotein-apolipoprotein B metabolism following apheresis: simulation studies of mass changes and tracer kinetics. Metabolism. 1998;47:478\u201383.","journal-title":"Metabolism"},{"key":"787_CR60","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1194\/jlr.M300523-JLR200","volume":"45","author":"HC Geiss","year":"2004","unstructured":"Geiss HC, Bremer S, Barrett PH, Otto C, Parhofer KG. In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis. J Lipid Res. 2004;45:1459\u201367.","journal-title":"J Lipid Res"},{"key":"787_CR61","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0022-2275(20)37487-3","volume":"37","author":"KG Parhofer","year":"1996","unstructured":"Parhofer KG, Barrett PH, Demant T, Richter WO, Schwandt P. Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia. J Lipid Res. 1996;37:2383\u201393.","journal-title":"J Lipid Res"},{"key":"787_CR62","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0022-2275(20)31992-1","volume":"41","author":"KG Parhofer","year":"2000","unstructured":"Parhofer KG, Barrett PH, Demant T, Schwandt P. Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B. J Lipid Res. 2000;41:1596\u2013603.","journal-title":"J Lipid Res"},{"key":"787_CR63","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/MOL.0000000000000456","volume":"28","author":"KG Parhofer","year":"2017","unstructured":"Parhofer KG. New approaches to address dyslipidemia. Curr Opin Lipidol. 2017;28:452\u20137.","journal-title":"Curr Opin Lipidol"},{"key":"787_CR64","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","volume":"386","author":"S Tsimikas","year":"2015","unstructured":"\u2022 Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386:1472\u201383 The study shows that antisense-therapy can decrease Lp(a) dramatically (to a greater extent than apheresis). If available it would probably decrease the frequency of apheresis for elevated lipoprotein(a).","journal-title":"Lancet"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-019-0787-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-019-0787-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-019-0787-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T02:17:15Z","timestamp":1694830635000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-019-0787-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1007\/s11883-019-0787-5","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]},"assertion":[{"value":"1 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Gilbert Thompson declares no conflict of interest. Dr. Parhofer reports personal fees from Aegerion, Akcea, Amgen, Boehringer-Ingelheim, and MSD. Dr. Parhofer also reports grants from Novartis, grants and personal fees from Regeneron, grants and personal fees from Sanofi, all outside of the selected work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"26"}}